论文部分内容阅读
目的探讨坎地沙坦酯联合脑心通胶囊治疗高血压伴慢性脑供血不足脑血流灌注量的改善机制。方法选取我院2013年3月~2015年6月收治的120例高血压伴慢性脑供血不足患者为研究对象,采用随机数表法将患者分为观察组与对照组,每组60例。对照组采用脑心通治疗,观察组采用坎地沙坦酯联合脑心通胶囊治疗,比较两组脑血流灌注量改善情况,并分析改善机制。结果治疗后,观察组CBF、CBV分别为(32.47±7.75)ml/(min·100g)、(2.8 4±0.6 2)m l/(min·100g),与对照组比较显著较高(P<0.05),观察组血浆黏度、血小板聚集率、ET-1分别为(1.53±0.02)m Pa·s、(45.85±3.34)%、(65.35±10.98)ng/L,与对照组比较显著较低(P<0.05)。结论坎地沙坦酯联合脑心通胶囊可显著改善高血压伴脑供血不足患者的脑血流灌注量,可能与联合用药能降低患者血液黏滞度、抑制血小板聚集并降低血浆内皮素有关。
Objective To investigate the mechanism of candesartan cilexetil in combination with Naoxintong capsule in treating cerebral blood flow in patients with hypertension and chronic cerebral hypoperfusion. Methods A total of 120 patients with hypertension and chronic cerebral hypoperfusion who were treated in our hospital from March 2013 to June 2015 were selected as the research object. The patients were divided into observation group and control group by random number table method, with 60 cases in each group. The control group was treated with Naoxintong, and the observation group was treated with candesartan cilexetil and Naoxintong capsule. The improvement of cerebral blood flow perfusion was compared between the two groups, and the improvement mechanism was analyzed. Results After treatment, CBF and CBV in the observation group were significantly higher than those in the control group (32.47 ± 7.75 ml / (100 · 100g) and 2.8 ± 0.6 2 ml / (100 · 100g, P <0.05 ), And the plasma viscosity and platelet aggregation rate and ET-1 in the observation group were (1.53 ± 0.02) mPa · s, (45.85 ± 3.34)% and (65.35 ± 10.98) ng / L, P <0.05). Conclusions Candesartan cilexetil and Naoxintong capsule can significantly improve the cerebral blood perfusion in hypertensive patients with cerebral insufficiency, which may be related to the combination therapy can reduce blood viscosity, inhibit platelet aggregation and decrease plasma endothelin.